{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:51:11Z","timestamp":1785401471386,"version":"3.56.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Gilead Sciences, Inc., Foster City, CA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the long-term safety and efficacy of filgotinib (FIL) for Japanese patients with rheumatoid arthritis (RA) and limited\/no prior methotrexate (MTX) exposure. We present a Japanese population subanalysis of a global randomised-controlled trial at Week 52 and interim long-term extension (LTE) to Week 48 through June 2020.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients were randomised to FIL 200\u2009mg plus MTX, FIL 100\u2009mg plus MTX, FIL 200\u2009mg, or MTX for 52\u2009weeks. At completion, eligible patients could enrol in the LTE. Those receiving FIL continued; those receiving MTX were rerandomised (blinded) to FIL 200 or 100\u2009mg upon discontinuation of MTX. After a 4-week washout period, MTX could be re-added.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Adverse event rates at Week 52 and in the LTE to Week 48 were comparable across treatment groups. Week 52 American College of Rheumatology 20% improvement (ACR20) rates were 83% (19\/23), 82% (9\/11), 75% (9\/12), and 76% (19\/25) for FIL 200\u2009mg plus MTX, FIL 100\u2009mg plus MTX, FIL 200\u2009mg, and MTX, respectively. Through LTE Week 48, ACR20 rates were maintained.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In the 56 Japanese patients treated with FIL, efficacy was maintained through Week 52 and beyond, with no increases in the incidence of adverse events.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roac083","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T16:57:40Z","timestamp":1659545860000},"page":"657-667","source":"Crossref","is-referenced-by-count":10,"title":["Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients na\u00efve to MTX treatment (FINCH 3)"],"prefix":"10.1093","volume":"33","author":[{"given":"Tatsuya","family":"Atsumi","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University , Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan , Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Matsubara Mayflower Hospital , Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University , Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Aichi Developmental Disability Center , Kasugai, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital , Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8858-9435","authenticated-orcid":false,"given":"Kunihiro","family":"Yamaoka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine , Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Westhovens","sequence":"additional","affiliation":[{"name":"Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven , Leuven, Flanders, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W T","family":"Ching","sequence":"additional","affiliation":[{"name":"Timaru Medical Specialists Limited, Level 1 , Timaru, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osvaldo Daniel","family":"Messina","sequence":"additional","affiliation":[{"name":"Cosme Argerich Hospital and Investigaciones Reumatologicas y Osteologicas SRL IRO , Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd R","family":"Burmester","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9\u2014University Medicine Berlin, Free University and Humboldt University , Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Genovese","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. , Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrix","family":"Bartok","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. , Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Pechonkina","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. , Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kondo","sequence":"additional","affiliation":[{"name":"Gilead Sciences K.K. , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyu","family":"Yin","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. , Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Gong","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. , Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Tasset","sequence":"additional","affiliation":[{"name":"Galapagos NV , Mechelen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"key":"2023070502120511000_R1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00296-020-04731-0","article-title":"The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review","volume":"41","author":"Almutairi","year":"2021","journal-title":"Rheumatol Int"},{"key":"2023070502120511000_R2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3109\/14397595.2013.854059","article-title":"Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I)","volume":"24","author":"Yamanaka","year":"2014","journal-title":"Mod Rheumatol"},{"key":"2023070502120511000_R3","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023070502120511000_R4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/14397595.2018.1472358","article-title":"Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis","volume":"29","author":"Kameda","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2023070502120511000_R5","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023070502120511000_R6","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023070502120511000_R7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"2023070502120511000_R8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/annrheumdis-2020-219213","article-title":"Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial","volume":"80","author":"Westhovens","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023070502120511000_R9","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023070502120511000_R10","article-title":"Gilead Sciences, K.K. Jyseleca\u00ae (filgotinib) Japanese prescribing information. 2020"},{"key":"2023070502120511000_R11","article-title":"European Medicines Agency. Filgotinib (Jyseleca\u00ae): summary of product characteristics. 2022"},{"key":"2023070502120511000_R12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/mr\/roab021","article-title":"Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3)","volume":"32","author":"Atsumi","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2023070502120511000_R13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/14397595.2020.1859675","article-title":"Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: subgroup analyses of a global phase 3 study (FINCH 2)","volume":"32","author":"Takeuchi","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2023070502120511000_R14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/mr\/roab030","article-title":"Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1)","volume":"32","author":"Tanaka","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2023070502120511000_R15","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/art.39670","article-title":"Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2023070502120511000_R16","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3899\/jrheum.161196","article-title":"Association between medications and herpes zoster in Japanese patients with rheumatoid arthritis: a 5-year prospective cohort study","volume":"44","author":"Harada","year":"2017","journal-title":"J Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac083\/45476167\/roac083.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/4\/657\/50797262\/roac083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/4\/657\/50797262\/roac083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T03:04:13Z","timestamp":1688526253000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/4\/657\/6654741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,8,3]]},"published-print":{"date-parts":[[2023,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac083","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2022,8,3]]}}}